Amgen Inc. Stock

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-16 pm EDT 5-day change 1st Jan Change
265.6 USD +0.05% Intraday chart for Amgen Inc. -1.75% -7.77%
Sales 2024 * 32.99B Sales 2025 * 34.12B Capitalization 142B
Net income 2024 * 6.12B Net income 2025 * 7.57B EV / Sales 2024 * 5.73 x
Net Debt 2024 * 46.74B Net Debt 2025 * 40.74B EV / Sales 2025 * 5.36 x
P/E ratio 2024 *
23.1 x
P/E ratio 2025 *
17.8 x
Employees 26,700
Yield 2024 *
3.49%
Yield 2025 *
3.78%
Free-Float 99.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.79%
1 week-1.37%
Current month-6.62%
1 month-1.25%
3 months-13.38%
6 months-6.54%
Current year-7.82%
More quotes
1 week
264.35
Extreme 264.345
273.00
1 month
264.35
Extreme 264.345
288.57
Current year
264.35
Extreme 264.345
329.72
1 year
211.71
Extreme 211.71
329.72
3 years
198.64
Extreme 198.64
329.72
5 years
166.30
Extreme 166.3
329.72
10 years
108.20
Extreme 108.2
329.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 06-05-31
Director of Finance/CFO 65 19-10-22
Chief Tech/Sci/R&D Officer 52 Dec. 17
Members of the board TitleAgeSince
Director/Board Member 67 17-02-02
Director/Board Member 68 16-10-13
Director/Board Member 75 14-10-16
More insiders
Date Price Change Volume
24-04-16 265.6 +0.05% 2,017,573
24-04-15 265.5 -0.66% 1,740,174
24-04-12 267.3 -1.01% 2,140,134
24-04-11 270 +1.33% 2,169,844
24-04-10 266.4 -1.45% 1,949,622

Delayed Quote Nasdaq, April 15, 2024 at 04:00 pm EDT

More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
265.5 USD
Average target price
304.5 USD
Spread / Average Target
+14.67%
Consensus